Site navigation
Our sites
One of the big mysteries in the research on an HIV cure might have its explanation in hepatitis C. It’s seen as the greatest challenge in HIV (human immunodeficiency virus)…
From 1 September 2026, the prescriber accreditation requirement for hepatitis B medicines under the PBS Section 100 (s100) Highly Specialised Drugs (HSD) Program will be removed. As a result, all…
Sydney-based pharmaceutical company Biotron is investigating a new drug candidate that shows promise in treating both hepatitis B and hepatitis D. Hepatitis B on its own is in desperate need…
The Senate has voted to establish a new inquiry into Australia’s infected blood scandal. This follows a recent ABC Australian Story episode on contaminated blood products has brought the topic…
As Australia struggles to meet its 2030 targets for viral hepatitis elimination, it is instructive to look at successes elsewhere in the world. Four Nations Seeking Elimination As an example,…
Australia faces more than $2.6 billion in avoidable costs by 2030 if it fails to meet national hepatitis B and hepatitis C elimination targets, new modelling released by Hepatitis Australia…
Hepatitis Australia and Hepatitis SA are reminding all Australians, particularly anyone who received a blood transfusion or blood product before donor screening began in 1990, that hepatitis C is curable,…
Hepatitis SA educators are offering Paint and Learn sessions where participants have fun painting on canvases as they learn and chat about viral hepatitis and blood borne viruses. This approach…
There is a significant association between living with the hepatitis C virus and suffering from overactive bladder syndrome (OAB), according to a study published in the journal BMC Urology. The bladder has a…
A new national hepatitis C telehealth service is making it easier for people to get assessed, tested and treated for hepatitis C in Australia. Launched in June by Hepatitis Australia,…
New data from the Penington Institute has revealed that 2,272 Australians died of drug-induced deaths in 2023, with the rate of unintentional overdoses increasing to nearly 80 per cent. On average,…
Pharmaceutical giant, GSK, who seem to be leading the field in developing a hepatitis B functional cure, has finally presented the results on their new drug, bepirovirsen. The 254 million…
Powerful new data from the 2024 annual report for Measuring the progress towards the targets of the National Hepatitis B Strategy (launched by The Peter Doherty Institute at the end…
The use of performance and image enhancing drugs (PIEDs) is growing. While reliable data about the number of people in the community who use them is hard to find, PIED…
Hepatitis SA’s harm reduction peer services is encouraging clients and community members to consider lung cancer screening with the Australian government’s free lung screen program. Screening is a way of…
Pharmaceutical giant GSK has announced that it has entered into an exclusive collaboration with the Hong Kong-based pharma company Sino Biopharmaceutical to sell in mainland China, a chronic hepatitis B…
Urgent scale-up of global action is needed if the world is to meet its target of eliminating viral hepatitis by 2030. This was the clear message from the World Health…
A clinical trial led by the Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as effective as traditional laboratory testing, paving the way…
Chronic hepatitis B is substantially prevalent across Europe, affecting an estimated 0.7 per cent of the population in the region in 2022, according to a new study published in Eurosurveillance. While this…
By Peter Breadon, Grattan Institute and Mia Jessurun, Grattan Institute Child vaccination has been one of Australia’s biggest success stories. Before the COVID pandemic, we hit the national target of…
One in nine people in prisons globally have a history of injecting drug use and their risk of HIV, viral hepatitis and tuberculosis is up to 45 times higher than…
A drug that is already in clinical trials against the hepatitis C virus (HCV) has been shown to be excellent at also preventing the hepatitis E virus (HEV) from replicating.…
Australia has taken a significant step in its commitment to ending hepatitis B and C as public health challenges, with the launch of the Fourth National Hepatitis B Strategy 2025–2030 and…
Ten years ago, on 1 March 2016, Australia became the first country to publicly subsidise new direct-acting antiviral (DAA) hepatitis C treatments for the entire population, no matter their condition…
August 2026
